Sergey Orlov

5.4k citations

149 papers · 2.0k indexed · 1 hit paper · h-index 21

Impact in

Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies

Papers in ⓘ

Pulmonary and Respiratory Medicine 77
- Lung Cancer Treatments and Mutations 65
- Lung Cancer Diagnosis and Treatment 24
Oncology 64
- Lung Cancer Research Studies 35
- Colorectal Cancer Treatments and Studies 15
- Cancer Immunotherapy and Biomarkers 9

Co-authors: Dizhe Eb (31 shared papers)Perevozchikov Ap (25 shared papers)Vladimir S. Shavva (25 shared papers)Denis A. Mogilenko (18 shared papers)Wu‐Chou Su (11 shared papers)Lecia V. Sequist (11 shared papers)James Chih‐Hsin Yang (9 shared papers)S. V. Burov (5 shared papers)
Journals: Journal of Clinical Oncology (27 papers)Annals of Oncology (24 papers)Journal of Thoracic Oncology (12 papers)Journal of Biological Chemistry (3 papers)Journal of Cellular Biochemistry (2 papers)
Partner nations: Russia United States South Korea

In The Last Decade

Sergey Orlov

144 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study 2020 · 295 citations

Peers

Countries citing papers authored by Sergey Orlov

Since Specialization

Citations

This map shows the geographic impact of Sergey Orlov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergey Orlov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergey Orlov more than expected).

Fields of papers citing papers by Sergey Orlov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergey Orlov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergey Orlov. The network helps show where Sergey Orlov may publish in the future.

Co-authors

The 25 scholars most cited alongside Sergey Orlov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sergey Orlov Line = papers co-authored together Sergey Orlov links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 149 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study The Lancet Oncology ·Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Lone H. Ottesen, Paul Frewer, Xiaoling Ou, Geoffrey R. Oxnard Hit paper breakdown →	2020	295
2	Complexes of Plasmid DNA with Basic Domain 47-57 of the HIV-1 Tat Protein Are Transferred to Mammalian Cells by Endocytosis-mediated Pathways Journal of Biological Chemistry ·I. A. Ignatovich, Dizhe Eb, Anna V. Pavlotskaya, B. N. Akifiev, S. V. Burov, Sergey Orlov, Perevozchikov Ap	2003	171
3	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology ·James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist	2012	136
4	Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Journal of Clinical Oncology ·Juergen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaër, Anna Robeva, Maeve Waldron-Lynch, Rebecca S. Heist	2019	84
5	Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study American Journal of Hematology ·Carlo Gambacorti‐Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin‐Seok Ahn, J. Thaddeus Beck, W. Jeffrey Edenfield, Yuankai Shi, Matthew H. Taylor, Kenji Tamura, Brian A. Van Tine, Shang‐Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim	2018	74
6	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Enriqueta Felip, Sergey Orlov, Keunchil Park, Chong‐Jen Yu, Chun‐Ming Tsai, Makoto Nishio, Manuel Cobo, Mark J. McKeage, Wu‐Chou Su, Tony Mok, Giorgio V. Scagliotti, David R. Spigel, Fabrice Branle, Chetachi A. Emeremni, Massimiliano Quadrigli, Alice T. Shaw	2015	67
7	Role of the Nuclear Receptors HNF4α, PPARα, and LXRs in the TNFα-Mediated Inhibition of Human Apolipoprotein A-I Gene Expression in HepG2 Cells Biochemistry ·Denis A. Mogilenko, Dizhe Eb, Vladimir S. Shavva, Ivan A. Lapikov, Sergey Orlov, Perevozchikov Ap	2009	62
8	One-stage allotransplantation of thoracic segment of the trachea in a patient with idiopathic fibrosing mediastinitis and marked tracheal stenosis European Journal of Cardio-Thoracic Surgery ·Yuri N. Levashov, P. K. Yablonsky, S. M. Cherny, Sergey Orlov, B. B. Shafirovsky, I KUZNETZOV	1993	55
9	Modified Low Density Lipoprotein Stimulates Complement C3 Expression and Secretion via Liver X Receptor and Toll-like Receptor 4 Activation in Human Macrophages Journal of Biological Chemistry ·Denis A. Mogilenko, И. В. Кудрявцев, Andrey S. Trulioff, Vladimir S. Shavva, Dizhe Eb, Boris V. Missyul, A. Zhakhov, A. Ischenko, Perevozchikov Ap, Sergey Orlov	2011	52
10	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology ·James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Robert M. Lorence, Maryam Shahidi, Lecia V. Sequist	2012	52
11	Peroxisome Proliferator-activated Receptor α Positively Regulates Complement C3 Expression but Inhibits Tumor Necrosis Factor α-mediated Activation of C3 Gene in Mammalian Hepatic-derived Cells Journal of Biological Chemistry ·Denis A. Mogilenko, И. В. Кудрявцев, Vladimir S. Shavva, Dizhe Eb, Ekaterina G. Vilenskaya, A. M. Efremov, Perevozchikov Ap, Sergey Orlov	2012	43
12	Endogenous apolipoprotein A‐I stabilizes ATP‐binding cassette transporter A1 and modulates Toll‐like receptor 4 signaling in human macrophages The FASEB Journal ·Denis A. Mogilenko, Sergey Orlov, Andrey S. Trulioff, А. В. Иванов, Vadim K. Nagumanov, И. В. Кудрявцев, Vladimir S. Shavva, D. A. Tanyanskiy, Perevozchikov Ap	2012	39
13	A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. Journal of Clinical Oncology ·Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt, Mary O’Brien, David R. Spigel, Lucio Crinò, Chun‐Ming Tsai, Joo-Hang Kim, Eun Kyung Cho, Aleksandra Szczęsna, Otto C. Burghuber, Philip C. Hoffman, Shaf Keshavjee, Sergey Orlov, Piotr Serwatowski, Jiuzhou Wang, Margaret A. Foley, Julie D. Horan, Jung Wook Park, Frances A. Shepherd, (unknown)	2014	37
14	PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells Biochemical and Biophysical Research Communications ·Denis A. Mogilenko, Vladimir S. Shavva, Dizhe Eb, Sergey Orlov, Perevozchikov Ap	2010	34
15	Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain Annals of Oncology ·Laura Q.M. Chow, Fabrice Barlési, Erin M. Bertino, Martin J. van den Bent, Heather A. Wakelee, Patrick Y. Wen, Chao‐Hua Chiu, Sergey Orlov, Margarita Majem, Rita Chiari, Mark J. McKeage, Chong‐Jen Yu, Felipe K. Hurtado, Pilar Cazorla Arratia, Yuanbo Song, Fabrice Branle, M. Shi, D.-W. Kim	2019	32
16	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler	2023	30
17	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC Journal of Thoracic Oncology ·Makoto Nishio, Enriqueta Felip, Sergey Orlov, Keunchil Park, Chong‐Jen Yu, Chun-Ming Tsai, Manuel Cobo, Mark J. McKeage, Wu‐Chou Su, Tony Mok, Giorgio V. Scagliotti, David R. Spigel, Kalyanee Viraswami-Appanna, Zhe Chen, Vanessa Q. Passos, Alice T. Shaw	2019	28
18	Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC) Annals of Oncology ·Jennifer Moriatis Wolf, Takashi Seto, Han Jin, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Tomoyuki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, P.-J. Souquet, Johan Vansteenkiste, Marco Giovannini, Sylvie Le Mouhaër, Anna Robeva, Maeve Waldron-Lynch, Rebecca S. Heist	2018	27
19	Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. Journal of Clinical Oncology ·Martin Reck, R. Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, José Barrueco, Birgit Gaschler‐Markefski, Silvia Novello	2013	23
20	Novel repressor of the humanFMR1gene − identification of p56 human (GCC)_n‐binding protein as a Krüppel‐like transcription factor ZF5 FEBS Journal ·Sergey Orlov, Konstantin Kuteykin‐Teplyakov, I. A. Ignatovich, Dizhe Eb, O. A. Mirgorodskaya, Grishin Av, Olga B. Guzhova, Egor Prokhortchouk, Pavel V. Guliy, Perevozchikov Ap	2007	22

About Sergey Orlov

Sergey Orlov is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Hepatology and Biological Psychiatry, having authored 149 papers that have together received 2.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (35 papers), Lung Cancer Diagnosis and Treatment (24 papers), Peroxisome Proliferator-Activated Receptors (16 papers), Colorectal Cancer Treatments and Studies (15 papers), Cholesterol and Lipid Metabolism (10 papers), Cancer, Lipids, and Metabolism (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.0k citations), Oncology (867 citations), Cancer Research (293 citations), Hepatology (114 citations) and Molecular Biology (804 citations). Sergey Orlov has collaborated with scholars based in Russia, United States and South Korea. Frequent co-authors include Dizhe Eb, Perevozchikov Ap, Vladimir S. Shavva, Denis A. Mogilenko, Wu‐Chou Su, Lecia V. Sequist, James Chih‐Hsin Yang, S. V. Burov, Ji‐Youn Han and Anders Mellemgaard. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Journal of Biological Chemistry and Journal of Cellular Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact